Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 4/20 | 0.45 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.43 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.43 |
| ▸ | NOS3 | P29474 | 1/20 | 0.40 |
| ▸ | NOS1 | P29475 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17721727 | 0.78 | TKT (0.34) | NOS3NOS1NOS2 | |
| SCHEMBL13693762 | 0.78 | LMNA (0.38) | NOS3NOS1NOS2 | |
| SCHEMBL18799338 | 0.76 | DHFR (0.38) | DHFRP2RX3P2RX2 | |
| SCHEMBL12316236 | 0.75 | P2RX3 (0.47) | DHFRP2RX3P2RX2 | |
| SCHEMBL29941363 | 0.75 | DHFR (0.64) | DHFR | |
| SCHEMBL1317193 | 0.75 | DHFR (0.64) | DHFR | |
| SCHEMBL27051314 | 0.74 | GABRP (0.41) | DHFRNOS3NOS1NOS2 | |
| SCHEMBL8201952 | 0.74 | NUDT1 (0.42) | DHFRP2RX3P2RX2NOS3NOS1 | |
| SCHEMBL25147465 | 0.74 | DHFR (0.49) | DHFRP2RX3P2RX2NOS3NOS1 | |
| SCHEMBL28150953 | 0.74 | DHFR (0.49) | DHFRP2RX3P2RX2NOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230117631-A1 | HPK1 ANTAGONISTS AND USES THEREOF | Nimbus Saturn, Inc. | 2023-04-20 | — | — | US | disclosed |
| US-8263648-B2 | Diebenzofuran derivatives as inhibitors of PDE-4 and PDE-10 | Mylan Laboratories Ltd. (IN) | 2012-09-11 | — | — | US | disclosed |
| US-20090281131-A1 | DIEBENZOFURAN DERIVATIVES AS INHIBITORS OF PDE-4 AND PDE-10 | MYLAN LABORATORIES LIMITED (IN) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230117631-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | DHFR 3752/4885P2RX3 2136/4885P2RX2 2257/4885 |
| US-20090281131-A1 | DIEBENZOFURAN DERIVATIVES AS INHIBITORS OF PDE-4 AND PDE-10 | PDE4A, PDE4B, PDE12 | DHFR 201/4885P2RX3 992/4885P2RX2 1041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.